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Abstract
Background: Cardiac amyloidosis is a progressive but underdiagnosed and underappreciated cause of heart
failure. In the last few years, cardiovascular magnetic resonance (CMR) has become the gold standard for
non invasive diagnosis of cardiac amyloidosis with the characteristic subendocardial late gadolinium
enhancement.
Case presentation: We describe a case of a patient who, in the process of aligning protocols for a trial
between different centers, had a paired study with two different contrast agents, Dotarem® and MultiHance®.
MultiHance® surprisingly failed to demonstrate the characteristic imaging pattern, showing only non specific
late gadolinium enhancement at the inferior right ventricular insertion point and different myocardial
extracellular volume fraction compared to the one obtained with Dotarem®. MultiHance® is used by many
centres, because its partial blood protein binding is a strength for MR angiography, but late gadolinium
enhancement, particularly non-ischemic, appears to be compromised.
Conclusions: This case report suggests that contrast agents should be selected with caution, especially with
new therapies lining up for amyloid and CMR being used as exploratory end point in clinical trials.
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Background
In the last decade, cardiovascular magnetic resonance
(CMR) has grown dramatically and in amyloidosis has
become the gold standard for non invasive diagnosis
of cardiac involvement with the characteristic suben-
docardial late gadolinium enhancement (LGE) [1].
The number of new referrals for cardiac amyloidosis
has significantly increased in the last few years, with
the diagnosis being based on CMR and the character-
istic LGE. New contrast agents favoured for their high
relaxivity related to blood protein binding, [2] have
become available but no one has ever tested the diag-
nostic performance of these new agents in infiltrative
disease.
Case presentation
A 77-year old man presented with breathlessness and
weight loss. Endoscopy and duodenal biopsy showed
amyloid deposits, subtyped as transthyretin type
(TTR). Investigations excluded a plasma cell dyscrasia,
and showed atrial fibrillation on ECG (Fig. 1), and
moderately increased wall thickness with moderate to
severe diastolic dysfunction on echocardiography
(Fig. 2, videos available as Additional files 1 and 2).
TTR gene sequencing showed no mutation so the
diagnosis was that of wild-type ATTR amyloidosis (senile
systemic amyloidosis). Cardiac involvement, though likely,
was not unequivocal as age/hypertension can confound.* Correspondence: j.moon@ucl.ac.uk
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Technetium-labelled bone scintigraphy and CMR were
performed. Scintigraphy demonstrated grade 2 myocardial
uptake, highly specific for cardiac amyloidosis. Cine
CMR imaging supported the echocardiographic and
scintigraphy findings. Tissue characterization showed
clear amyloidosis with elevated native myocardial T1
(ShMOLLI, 1072 ms, normal 960 ms+/-30 ms) and,
after contrast (Gadoterate meglumine, 0.1 mmol/kg,
gadolinium-DOTA, Dotarem® Guerbet S.A. France),
abnormal gadolinium kinetics on TI scout (nulling of
the myocardium before the blood) and diffuse biven-
tricular subendocardial LGE (Fig. 2) [1]. The extracel-
lular volume fraction (ECV) at 15 min was 0.53.
Two weeks later, the CMR was repeated (same scanner
and team with no changes in the patient regarding
treatment or disease status) within the screening tests of a
clinical trial, this time with a different contrast agent,
gadobenate dimeglumine (0.1 mmol/kg, gadolinium-
BOPTA, MultiHance®, Bracco, Milan, Italy). The cines and
native T1 findings were the same (Fig. 3). The LGE how-
ever was markedly different – the subendocardial LGE
so characteristic of amyloidosis was not visible, even
with phase-sensitive inversion recovery (PSIR). There
was just non-specific right ventricle insertion point
LGE (Fig. 4). The ECV at 15 min obtained using Gd-
BOPTA (MultiHance®) was now lower – 0.45 compared
to 0.53 with gadolinium-DOTA (Dotarem®) (same ac-
quisition time after contrast administration). This dif-
ference is higher than the expected variability of the
technique. Prior publications demonstrate the ECV to
Fig. 1 Twelve lead ECG at presentation showing atrial fibrillation
Fig. 2 Parasternal long axis (left) and apical four-chamber (right) views echocardiography images. Videos are available as Additional files 1 and 2
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be stable to a standard deviation of 0.02 (0.03 for
amyloid); [3] here a 0.08 difference with contrast
agent is recorded.
Discussion
Gd-BOPTA (MultiHance®) is an ionic linear chelate
favoured for its high relaxivity related to blood pro-
tein binding, [2] which also makes it a partially
“intra-vascular” contrast agent. Here, paired scanning
performed serendipitously for a clinical trial failed to
demonstrate the characteristic pattern of myocardial
amyloidosis, and performed poorly compared to
gadoterate meglumine. MultiHance® is widely used
for CMR. This effect was unexpected – but theoret-
ical concerns had been raised for ECV mapping with
protein bound contrast agents [4]. Due to difference
in relaxivity between the contrast agents, some
Authors proposed the use of a lower dose of Gd-
BOPTA for reaching similar T1 and ECV values. In
this case the same dose was used for both contrasts
and this could explain in part the differences ob-
served. In this case, the use of MultiHance® did not
affect the diagnosis, but reporting the MultiHance®
CMR in isolation without the previous work-up by the
National Amyloid Centre could have conceivably led to a
misdiagnosis.
Conclusion
We suggest that protein bound agents for interstitial
enhancement of non-ischaemic cardiomyopathy (myo-
cardium, ECV measurement) should be used with cau-
tion whilst further work is undertaken as the diagnostic
performance may not be the same as non-protein
bound variants.
Fig. 3 Short axis ShMOLLI T1 mapping images pre-contrast (top) and post-contrast (bottom) with gadolinium-DOTA, Dotarem® (a) and
with gadolinium-BOPTA, MultiHance® (b). Myocardial T1 post-contrast = 486 ms and blood T1 post-contrast =506 ms 15 min after
gadolinium-DOTA, Dotarem®; and myocardial T1 post-contrast = 344 ms and blood T1 post-contrast = 287 ms 15 min after
gadolinium-BOPTA, MultiHance®
Fig. 4 CMR end-diastolic cine (a); late gadolinium images with Magnitude-FLASH (b) and late gadolinium images with PSIR-FLASH (c) after
gadolinium-DOTA, Dotarem® showing the classic amyloid global, subendocardial late gadolinium enhancement pattern; late gadolinium
images with Magnitude-FLASH (d) and late gadolinium images with PSIR-FLASH (e) after gadolinium-BOPTA MultiHance®, showing no
features of amyloid
Fontana et al. BMC Medical Imaging  (2017) 17:3 Page 3 of 4
Additional files
Additional file 1: Video 1. Echocardiogram: apical four chamber view.
(AVI 5448 kb)
Additional file 2: Video 2. Echocardiogram: parasternal long axis view.
(AVI 5765 kb)
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